Skip to content

US · SMTI · MEDICAL - INSTRUMENTS & SUPPLIES

Sanara MedTech Inc. (SMTI) intrinsic value and stock valuation

$32.55as of 2026-11-21 · Mkt cap 313.48M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Sanara MedTech Inc. DCF and intrinsic value

InvestorsCraft values SMTI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SMTI’s statements →

Sanara MedTech Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Fort Worth, TX 76102 sanaramedtech.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$103.1M+45.9% 5y CAGRd
20112025
Net income
-$-37.56M
20112025
Free cash flow
$2.16M
20112025
Total equity
$5.93M+0.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$103.1M$86.7M$65M$45.8M$24.1M
Operating income$9.15M-$-6.72M-$-4.22M-$-12.52M-$-7.38M
Net income-$-37.56M-$-9.66M-$-4.3M-$-7.94M-$-7.92M
EPSd-$-4.36M-$-1.14M-$-519.32K-$-1M-$-1.08M
Operating cash flow$6.79M-$-20K-$-3.25M-$-5.55M-$-4.81M
Capital expenditure-$-4.63M-$-230K-$-270K-$-750K-$-750K
Free cash flow$2.16M-$-250K-$-3.51M-$-6.3M-$-5.56M
Total assets$72.9M$88.1M$73.9M$61M$36.4M
Total debt$48.2M$32.3M$11.8M$820K$430K
Net debt$31.6M$16.4M$6.64M-$-8.14M-$-18.23M
Total equity$5.93M$38.9M$44.6M$41.7M$30.2M
Cash and short-term investments$16.6M$15.9M$5.15M$8.96M$18.7M
Income statement
20252024202320222021
Revenue$103.1M$86.7M$65M$45.8M$24.1M
Cost of revenue$10.2M$8.14M$7.85M$6.36M$2.31M
Gross profit$92.9M$78.5M$57.1M$39.5M$21.8M
Research and development expenses$5.07M$5.7M$4.13M$3.37M$560K
Selling, general and administrative expenses$78.7M$76.6M$57M$46M$28.1M
Other expenses$0.00$2.98M$230K$2.66M$600K
Operating expenses$83.8M$85.3M$61.4M$52M$29.2M
Cost and expenses$94M$93.4M$69.2M$58.4M$31.5M
Interest income$0.00$20K$0.00$280K$0.00
Interest expense$6.76M$3.13M$480K$280K$0.00
Depreciation and amortization$2.66M$4.92M$3.68M$2.37M$770K
Ebitda$9.03M-$-1.86M-$-290K-$-11.57M-$-7.22M
Operating income$9.15M-$-6.72M-$-4.22M-$-12.52M-$-7.38M
Total other income/expenses, net-$-9.54M-$-3.2M-$-220K-$-1.42M-$-620K
Income before tax-$-390K-$-9.91M-$-4.44M-$-13.94M-$-7.99M
Income tax expense$0.00$0.00$0.00-$-5.84M$0.00
Net income-$-37.56M-$-9.66M-$-4.3M-$-7.94M-$-7.92M
Weighted average shares outstanding$8.62M$8.48M$8.28M$7.91M$7.34M
Weighted average diluted shares outstanding$8.62M$8.48M$8.28M$7.91M$7.34M
Balance sheet
20252024202320222021
Cash and short-term investments$16.6M$15.9M$5.15M$8.96M$18.7M
Net receivables$12M$13.6M$8.53M$7M$2.99M
Inventory$3.95M$2.75M$4.72M$3.55M$2.05M
Total current assets$33.5M$33.3M$19M$20.6M$24.6M
Property, plant and equipment, net$2.53M$1.88M$3.25M$2.22M$2.04M
Goodwill and intangible assets$22.2M$44.6M$48.5M$35.1M$4.73M
Long-term investments$14.6M$8.3M$3.08M$3.08M$5.02M
Total non-current assets$39.4M$54.8M$54.9M$40.4M$11.8M
Total assets$72.9M$88.1M$73.9M$61M$36.4M
Accounts payable$2.34M$1.5M$2M$1.43M$590K
Short-term debt$350K$360K$940K$310K$200K
Deferred revenue$1.23M$0.00$2.05M$0.00$0.00
Total current liabilities$18.6M$15.3M$13.8M$12.8M$6.02M
Long-term debt$47.8M$31.9M$10.9M$510K$220K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$48.4M$33.9M$15.5M$6.51M$220K
Capital lease obligations$1.87M$1.6M$2.1M$820K$430K
Total liabilities$67M$49.2M$29.3M$19.3M$6.24M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-75.3M-$-37.78M-$-28.04M-$-23.39M-$-15.24M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$5.93M$38.9M$44.6M$41.7M$30.2M
Total investments$14.6M$8.3M$3.08M$3.08M$5.02M
Total debt$48.2M$32.3M$11.8M$820K$430K
Net debt$31.6M$16.4M$6.64M-$-8.14M-$-18.23M
Cash flow statement
20252024202320222021
Net income-$-27.66M-$-9.91M-$-4.44M-$-8.09M-$-7.99M
Depreciation and amortization$28.6M$4.92M$3.68M$2.37M$600K
Stock-based compensation$720K$4.44M$3.44M$2.7M$2.67M
Change in working capital-$-3.84M-$-910K-$-3.28M$520K-$-1.18M
Accounts receivable$4.03M-$-4.54M-$-1.73M-$-2.27M-$-770K
Inventory-$-430K$1.44M-$-1.55M-$-520K-$-1.15M
Accounts payable$1.24M-$-470K$580K-$-420K$100K
Net cash provided by operating activities$6.79M-$-20K-$-3.25M-$-5.55M-$-4.81M
Investments in property, plant and equipment-$-4.42M-$-210K-$-270K-$-150K-$-170K
Acquisitions, net$0.00$0.00-$-9.94M-$-2.52M$0.00
Net cash used for investing activities-$-8.36M-$-6.61M-$-10.21M-$-3.51M-$-5.28M
Common stock issued$0.00$0.00$910K$0.00$28.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-8.48M$17.4M$9.64M-$-630K$28.3M
Net change in cash-$-10.03M$10.7M-$-3.81M-$-9.69M$18.2M
Cash at end of period$700K$15.9M$5.15M$8.96M$18.7M
Operating cash flow$6.79M-$-20K-$-3.25M-$-5.55M-$-4.81M
Capital expenditure-$-4.63M-$-230K-$-270K-$-750K-$-750K
Free cash flow$2.16M-$-250K-$-3.51M-$-6.3M-$-5.56M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Sanara MedTech Inc.

        Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.

        CEO
        Seth D. Yon
        Employees
        108
        Beta
        1.18

        Explore

        Frequently asked questions

        What is the intrinsic value of Sanara MedTech Inc. (SMTI)?

        InvestorsCraft does not currently publish an intrinsic value for SMTI. How the IC value is calculated.

        Is SMTI undervalued?

        InvestorsCraft does not publish an undervaluation signal for SMTI at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.